137
Participants
Start Date
October 6, 2014
Primary Completion Date
February 21, 2018
Study Completion Date
December 4, 2019
osilodrostat
Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.
LCI699 matching placebo
Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
Novartis Investigative Site, Vienna
Novartis Investigative Site, Sofia
Mount Sinai School of Medicine SC - LCI699C2301, New York
Columbia University Medical Center New York Presbyterian SC - LCI699C2301, New York
Memorial Sloan Kettering Cancer Center, New York
Novartis Investigative Site, Marseille
Novartis Investigative Site, Genova
University of Pennsylvania Clinical Studies Unit Unniv SC, Philadelphia
Novartis Investigative Site, Milan
The Johns Hopkins University School of Medicine Johns Hopkins University, Baltimore
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Emory University School of Medicine G2304 - C2301, Atlanta
Novartis Investigative Site, Pessac
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Padua
Novartis Investigative Site, Seville
University of Michigan Comprehensive Cancer Center, Ann Arbor
Medical College of Wisconsin MCW 2, Milwaukee
Novartis Investigative Site, Pisa
Novartis Investigative Site, Lille
Novartis Investigative Site, Ancona
Northwestern University SC - LCI699C2301, Chicago
Novartis Investigative Site, Paris
University of Colorado Hospital SC - LCI699C2301, Aurora
Novartis Investigative Site, Napoli
Novartis Investigative Site, München
Novartis Investigative Site, Songkhla
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Le Kremlin-Bicêtre
Oregon Health and Science University SC LCI699C2301, Portland
Novartis Investigative Site, Messina
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, New Delhi
Novartis Investigative Site, Moscow
Novartis Investigative Site, Chandigarh
Novartis Investigative Site, Bangalore
Novartis Investigative Site, Chengdu
Novartis Investigative Site, Vellore
Massachusetts General Hospital Neuroendocrine Unit, Boston
Novartis Investigative Site, CABA
Novartis Investigative Site, CABA
Novartis Investigative Site, Edmonton
Novartis Investigative Site, Halifax
Novartis Investigative Site, Montreal
Novartis Investigative Site, Sherbrooke
Novartis Investigative Site, Santiago de Cali
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Kobe
Novartis Investigative Site, Nishinomiya
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Bunkyo-ku
Novartis Investigative Site, Shinjuku-ku
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Sheffield
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY